These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 23496232)
1. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232 [TBL] [Abstract][Full Text] [Related]
2. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma. Wang S; Akhtar J; Wang Z Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168 [TBL] [Abstract][Full Text] [Related]
3. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells. Lin X; Liao Y; Chen X; Long D; Yu T; Shen F Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937 [TBL] [Abstract][Full Text] [Related]
4. Effects of stathmin 1 silencing by siRNA on sensitivity of esophageal cancer cells Eca-109 to paclitaxel. Zhu HW; Jiang D; Xie ZY; Zhou MH; Sun DY; Zhao YG Genet Mol Res; 2015 Dec; 14(4):18695-702. PubMed ID: 26782519 [TBL] [Abstract][Full Text] [Related]
5. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054 [TBL] [Abstract][Full Text] [Related]
6. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel. Rong F; Li W; Chen K; Li DM; Duan WM; Feng YZ; Li F; Zhou XW; Fan SJ; Liu Y; Tao M Neoplasma; 2012; 59(5):541-50. PubMed ID: 22668020 [TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and apoptosis of human B-cell lymphoma in vitro and in vivo by Bcl-2 short hairpin RNA. Liu Y; Shen Y; Qin C; Shi Y; Rong G; Yu X Oncol Rep; 2013 Jan; 29(1):244-52. PubMed ID: 23076380 [TBL] [Abstract][Full Text] [Related]
10. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347 [TBL] [Abstract][Full Text] [Related]
11. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297 [TBL] [Abstract][Full Text] [Related]
12. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Alli E; Yang JM; Ford JM; Hait WN Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681 [TBL] [Abstract][Full Text] [Related]
13. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2. Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244 [TBL] [Abstract][Full Text] [Related]
14. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells. Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928 [TBL] [Abstract][Full Text] [Related]
15. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Guo L; Zhou Y; Sun Y; Zhang F Eur J Cancer; 2010 Feb; 46(3):636-41. PubMed ID: 20004564 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression. Song Y; Mu L; Han X; Li Q; Dong B; Li H; Liu X J Neurooncol; 2013 Dec; 115(3):381-90. PubMed ID: 24043603 [TBL] [Abstract][Full Text] [Related]
17. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177 [TBL] [Abstract][Full Text] [Related]
18. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs]. Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142 [TBL] [Abstract][Full Text] [Related]
19. Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel. Feng W; Xiaoyan X; Xuan Y; Xiangke L; Zichang Y; Ran Z; Liuxing W; Qingxia F Cancer Gene Ther; 2015 Apr; 22(3):115-21. PubMed ID: 25572118 [TBL] [Abstract][Full Text] [Related]
20. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]